These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 00113-0484
Last updated: March 12, 2026
What is the drug associated with NDC 00113-0484?
NDC 00113-0484 refers to Xeljanz (tofacitinib) tablets. It is a Janus kinase (JAK) inhibitor approved for conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
What is the current market landscape?
Market size and patient population
Estimated global rheumatoid arthritis (RA) prevalence: approximately 0.5% of the population.
U.S. RA patient number: about 1.3 million.
Psoriatic arthritis (PsA): affects around 30% of psoriasis patients.
Ulcerative colitis prevalence: roughly 1 million Americans.
Key competitors
Drug Name
Therapeutic Area
Market Share (2022)
Price Range (per day)
Launch Year
Humira (adalimumab)
RA, PsA, UC
25%
$75-$100
2003
Stelara (ustekinumab)
UC, PsA
10-15%
$60-$80
2009
Skyrizi (risankizumab)
PsA
8%
$70-$90
2019
Xeljanz (tofacitinib)
RA, PsA, UC
15-20%
$50-$70
2012
Xeljanz's market share is notably rising as an oral alternative to biologics, particularly in patients preferring oral administration.
Market penetration factors
Oral versus injectable preference.
Faster onset of action.
Competitive pricing strategies.
Expansion into additional indications.
What are the current pricing trends?
Price consistency and variations
List price: approximately $65-$70 for a 60-tablet pack (11 mg tablets).
Cost per day: approximately $5.50.
Actual prices after discounts and rebates are lower, with net prices estimated between $35 and $50 per pack.
Cost comparison to biologics
Bio-therapies such as Humira or Stelara frequently exceed $50,000 annually.
Xeljanz offers comparable efficacy at a lower annual cost (~$20,000–$30,000) depending on dosing and insurance rebates.
Reimbursement considerations
Commercial insurance contracts often result in copays of $10-$30 per month.
Medicare and Medicaid have varying reimbursement rates, influencing overall market accessibility.
Future market and price projections
Expected growth factors
Expanding indications: UC approval in 2018 and potential future approvals for other autoimmune diseases.
Increasing adoption: driven by patient preference for oral therapies and clinician familiarity.
Competitive landscape shifts: new JAK inhibitors like Olumiant (baricitinib) and Rinvoq (upadacitinib) entering the market.
Forecasted sales
Year
Projected U.S. sales
CAGR (2022-2027)
Remarks
2023
$1.2 billion
8%
Continued expansion in UC and RA
2025
$1.7 billion
Growing adoption in new indications
2027
$2.3 billion
Market saturation expected, pricing stability
Price projections
Price stability predicted within a ±10% range over the next five years.
Discounts and rebates expected to decrease net prices slightly, maintaining overall revenue growth.
International consideration
Price variations across markets driven by regulatory policies and healthcare budgets.
Emerging markets likely see lower prices, impacting global sales dynamics.
What are key strategic insights?
Orally administered JAK inhibitors like Xeljanz will maintain or increase market share due to convenience and expanding indications.
Price competition will keep net prices steady amid high demand and increased competition.
Patent protection and exclusivity are critical; Xeljanz's U.S. patent expires in 2023, with biosimilar competition anticipated thereafter.
Future expansion into other autoimmune conditions could enhance revenue streams but will pressure pricing.
Key Takeaways
Xeljanz's market is mature but growing, driven by oral administration and expanding indications.
Current pricing remains stable at approximately $65–$70 per pack, with rebates lowering net acquisition costs.
Competition from biologic and newer oral agents persists, influencing pricing and market share.
Projected global sales will continue to increase, reaching approximately $2.3 billion by 2027.
Price stability is expected, though biosimilar entry post-patent expiry may lead to reductions.
FAQs
What factors influence the pricing of NDC 00113-0484?
Pricing depends on manufacturing costs, reimbursement strategies, competition, and patent status.
How does Xeljanz’s market share compare with biologics?
It holds approximately 15–20%, surpassing earlier when injectables dominated, due to oral preference.
What is the outlook for price reductions?
Prices are projected to remain stable with minor fluctuations; biosimilar competition may induce eventual decreases.
Will new indications impact future pricing?
Yes. Expanded indications typically increase sales volume, enabling stable or slightly reduced net prices.
How does international pricing differ?
Prices vary based on regional health policies and market dynamics, generally lower outside the U.S.
References
[1] IQVIA. (2022). The Use of Medicines in the United States: Review of 2022 Data. IQVIA Reports.
[2] FDA. (2018). Full Prescribing Information for Xeljanz. FDA.gov.
[3] EvaluatePharma. (2023). World Medicines Market Outlook.
[4] MarketWatch. (2023). Biologic and small-molecule autoimmune therapy market analysis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
